血液内科クリニカルスタンダード　第3版

出版社： 文光堂
著者：
発行日： 2015-10-04
分野： 臨床医学：内科  >  血液
ISBN： 9784830614248
電子書籍版： 2015-10-04 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

7,700 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

血液内科医や研修医，一般内科医にむけ，臨床血液学のクリニカルスタンダードをコンパクトかつ一歩踏み込んでまとめた実践的なマニュアル．好評の第2版から7年ぶりの改訂．本文は箇条書きで手順のみを示し，一目でわかる図表・写真・処方例を多用したデータブック的な要素を併せ持つ．箇条書きの本文では言い尽くせない詳しい説明はメモ書きで解説した．痒いところに手が届く，より臨床現場で役立つ内容となった．

目次

  • 血液内科クリニカルスタンダード　第3版

    ―目次―

    I．症候からのアプローチ
    　1．貧血
    　2．汎血球減少
    　3．出血傾向
    　4．血栓傾向
    　5．リンパ節腫脹

    II．診断と検査の重要ポイント
    　A．主要な検査
    　B．他科との連携

    III．治療の実際
    　A．造血器悪性腫瘍
    　B．貧血
    　C．止血血栓
    　D．その他
    　E．造血幹細胞移植

    IV．化学療法中の支持療法
    　1．腫瘍崩壊症候群
    　2．regimen-related toxicity
    　3．予防的抗菌薬投与
    　4．無菌管理
    　5．肝炎・肝機能障害
    　
    V．治療による合併症，処置中のトラブルへの対応
    　1．抗癌薬の血管外漏出への対応
    　2．抗癌薬の誤注
    　3．敗血症性ショックへの対応
    　4．電解質異常への対応
    　5．ステロイド糖尿病への対応
    　6．拘禁反応・せん妄への対応
    　7．針刺しへの対応
    　8．二次性悪性腫瘍

    VI．補助療法
    　1．抗菌薬の使用方法
    　2．サイトカイン療法
    　3．輸血
    　4．輸液調整の基本
    　5．症状緩和のための対症療法
    　6．腫瘤および播種性病変による合併症と対応

    VII．インフォームドコンセントに必要な治療成績，統計
    　1．急性白血病の治療成績
    　2．慢性骨髄性白血病の治療成績
    　3．悪性リンパ腫，慢性リンパ性白血病の治療成績
    　4．多発性骨髄腫の治療成績
    　5．再生不良性貧血，骨髄異形成症候群の治療成績
    　6．特発性血小板減少性紫斑病の治療成績

    VIII．巻末付録
    　1．performance status
    　2．体表面積
    　3．抗癌薬・分子標的治療薬の分類と副作用
    　4．腎不全時の抗癌薬の投与法
    　5．抗癌薬による心筋障害の評価と対応
    　6．抗菌薬のスペクトラム
    　7．染色体異常と臨床的意義
    　8．主要なCDとその意義
    　9．併用禁忌（注意）の薬剤
    　10．公的医療費助成申請の実際
    　11．血液内科疾患領域における
    　　　　保険適用，未適用医薬品および検査
    　12．検査基準値一覧
    　13．WHO分類第4版（2008年改訂）
    　14．参考図書，参考Web site
    　15．主要なガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 症候からのアプローチ

P.7 掲載の参考文献
1) World Health Organization : Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1) (http://www.who.int/vmnis/indicators/haemoglobin.pdf).
 
2) Cazzola M et al : Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997 ; 89 : 4248-67
 
P.11 掲載の参考文献
1) Ryan DH : Examination of the blood. Williams Hematology, 8th ed, Beutler E et al eds, McGraw-Hill, 2010, p11-24
 
P.18 掲載の参考文献
1) Rodgers RP et al : A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990 ; 16 : 1-20
 
2) Moake J : Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 2009 ; 22 : 567-76
 
3) Diz-kucukkaya R et al : Thrombocytopenia. Williams Hematology, 8th ed, Lichtman MA et al eds, McGraw-Hill, 2010, p1891-927
 
P.24 掲載の参考文献
1) Seligsohn U et al : Hereditary thrombophilia. Williams Hematology, 8th ed, Lichtman MA et al eds, McGraw-Hill, 2010, p2121-43
 
2) Raskob CE et al : Venous thrombosis. Williams Hematology, 8th ed, Lichtman MA et al eds, McGraw-Hill, 2010, p2185-96
 
3) Mohler ER : Atherothrombosis : disease initiation, progression, and treatment. Williams Hematology, 8th ed, Lichtman MA et al eds, McGraw-Hill, 2010, p2197-217
 
4) 宮田茂樹 : ヘパリン起因性血小板減少症. 臨床血液 2012 ; 53 : 1709-19
 
5) Albert CM et al : Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease : a randomized trial. JAMA 2008 ; 299 : 2027-36
 

II. 診断と検査の重要ポイント

P.41 掲載の参考文献
1) 秋山暢 : ベッドサイドのHematology, 3. 骨髄検査の意義と解釈. 内科 1997 ; 80 : 540-6
 
2) Lee SH et al : ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 2008 ; 30 : 349-64
 
3) 日野志郎 : 骨髄像 (含, 正常像). Medical Technology 1991 ; 19 : 614-20
 
4) Greer JP et al eds : Wintrobe's Clinical Hematology, 11th ed, Williams & Wilkins, 2004, p17
 
P.44 掲載の参考文献
1) Slap GB et al : When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984 ; 252 : 1321
PubMed
2) McCurley TL et al : Diagnostic approach to malignant and nonmalignant disorders of the phagocytic and immune systems. Wintrobe's Clinical Hematology, 12th ed, Greer JP et al eds, Williams & Wilkins, 2009, p1516-20
 
3) 須知泰山 : リンパ節生検-基本的取り扱い. リンパ節病変. 病理と臨床 1994 ; 12 (臨時増刊号) : 49-52
 
P.49 掲載の参考文献
1) Strupp M et al : Incidence of post-lumbar puncture syndrome reduced by reinserting the stylet : a randomized prospective study of 600 patients. J Neurol 1998 ; 245 : 589-92
 
P.59 掲載の参考文献
1) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, 2008
 
2) Bloomfield CD et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998 ; 58 : 4173-9
 
3) Licht JD et al : Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11 ; 17). Blood 1995 ; 85 : 1083-94
 
4) Pallisgaard N et al : Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998 ; 92 : 574-88
 
5) Mughes TP et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 2003 ; 349 : 1423-32
 
6) Radich J et al : Detection of bcr/abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997 ; 89 : 2602-9
 
P.71 掲載の参考文献
1) Asai S et al : A scoring system for ultrasonographic differentiation between cervical malignant lymphoma and benign lymphadenitis. 臨床病理 2001 ; 49 : 613-9
 
2) Kostakoglu L et al : Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma : is it time to shift gears? Eur J Nucl Med 2000 ; 27 : 1564-78
 
3) Juweid ME et al : Use of Positron Emission Tomography for Response Assessment of Lymphoma : Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007 ; 25 : 571-8
PubMed
4) 厚生労働省保険局医療課 : 事務連絡 疑義解釈資料の送付について (その1), 問147, 2012 (http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/iryouhoken15/dl/zimu2-1.pdf)
 
P.80 掲載の参考文献
1) Young NJA et al : Bilateral acute retinal necrosis. Br J Ophtalmol 1978 ; 62 : 581-90
 
2) 坂井潤一 : ウイルス性ぶどう膜炎・網膜炎. あたらしい眼科 1993 ; 10 : 729-35
 
3) 薄井紀夫 : 急性網膜壊死. 今日の眼疾患治療指針 第2版, 医学書院, 2007, p199-201
 
4) 藤野雄次郎 ほか : AIDS患者に発症したサイトメガロウイルス網膜炎に対するガンシクロビル硝子体注射療法. 日眼会誌 1996 ; 100 : 634-40
 
P.91 掲載の参考文献
1) 勝岡憲生ほか : 血管炎・血管障害ガイドライン. 日皮会誌 2008 ; 118 : 2095-187
 
2) 川名誠司 : Henoch-Schonlein紫斑 (アナフィラクトイド紫斑). MB Derma 2009 ; 156 : 8-13
 
3) 城野昌義 : 血液疾患, カラーアトラス皮膚病変を読む-全身疾患と皮膚, 宮地良樹ほか (編), 診断と治療社, 1988, p154-7
 
4) 勝岡憲生 : MDSと皮膚症状 (非特異疹). 皮膚臨床 1996 ; 38 : 451-7
 
5) Aste N et al : Nail pigmentation caused by hydroxyurea : report of 9 cases. J Am Acad Dermatol 2002 ; 47 : 146-7
 
6) 佐藤良夫 : 脱毛のメカニズム. 皮膚病診療 1979 ; 1 : 891-6
 
7) 服部友保ほか : Hydroxyureaにより生じた皮膚潰瘍と爪甲色素沈着. 皮膚科の臨床 2002 ; 44 : 1083-6
 
P.97 掲載の参考文献
1) 大屋夏生ほか : 血液・リンパ・皮膚. 放射線治療計画ガイドライン 2012年版, 日本放射線腫瘍学会 (編), 金原出版, 2012, p217-45
 
2) 伊丹純 : ホジキンリンパ腫. がん・放射線療法 2010, 大西洋ほか (編), 篠原出版, 2010, p1071-5
 
3) 小口正彦 : 非ホジキンリンパ腫. がん・放射線療法 2010, 大西洋ほか (編), 篠原出版, 2010, p1076-87
 
4) NCCN Clinical Practice Guidelines in Oncology : Non-Hodgkin's lymphomas, 2013 (http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf)
 
5) 坂田耕一 : 白血病. がん・放射線療法 2010, 大西洋ほか (編), 篠原出版, 2010, p1111-7
 

III. 治療の実際

P.113 掲載の参考文献
1) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, 2008
 
2) Bennett JM et al : Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985 ; 103 : 620-5
 
3) Miyawaki S et al : A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia : the Japan Adult Leukemia Study Group AML 97 Study. Cancer 2005 ; 104 : 2726-34
 
4) Zittoun RA et al : Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995 ; 332 : 217-23
 
5) Burnett AK et al : Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission : results of MRC AML 10 trial. Lancet 1988 ; 351 : 700-8
 
6) Cassileth PA et al : Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998 ; 339 : 1649-56
 
7) Grimwade D et al : Refinement of cytogenetic classification in acute myeloid leukemia : determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010 ; 116 : 354-65
 
8) 清井仁 : 急性骨髄性白血病. 血液専門医テキスト, 日本血液学会 (編), 南江堂, 2011, p241-51
 
9) Ohno R et al : Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 1993 ; 71 : 3888-95
 
10) Kobayashi T et al : Randomized trials between Behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J Clin Oncol 1996 ; 14 : 204-13
PubMed
11) Miyawaki S et al : No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia : the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999 ; 70 : 97-104
 
12) Ohno R et al : Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia : a double-blind controlled study. J Clin Oncol 1997 ; 15 : 2954-65
 
13) Ohtake S et al : Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia : the JALSG AML95 study. Int J Hematol 2010 ; 91 : 276-83
 
14) Ohtake S et al : Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia : the JALSG AML201 Study. Blood 2011 ; 117 : 2358-65
PubMed
15) Miyawaki S et al : A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood 2011 ; 117 : 2366-72
 
16) Bloomfield CD et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998 ; 58 : 4173-9
 
17) Byrd JC et al : Patients with t (8 ; 21) (q22 ; q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999 ; 17 : 3767-75
 
18) Tsimberidou AM et al : The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006 ; 132 : 398-409
 
P.121 掲載の参考文献
1) 原田結花ほか : 急性前骨髄球性白血病. 臨床血液 2013 ; 54 : 49-60
 
2) Sanz MA et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009 ; 113 : 1875-91
 
3) 品川克至 : Japan Adult Leukemia Study Group (JALSG) の臨床研究 : APL204. 血液フロンティア 2006 ; 16 : 1481-90
 
4) Asou N et al : A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy : The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007 ; 110 : 59-66
 
5) Tallman MS et al : All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997 ; 337 : 1021-8
 
6) Fenaux P et al : A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999 ; 94 : 1192-200
 
7) Shinagawa K et al : A phase III study of new synthetic retinoid tamibarotene (Am80) compared with ATRA in maintenance therapy for newly diagnosed acute promyelocytic leukemia (APL) : Japan Adult Leukemia Study Group (JALSG) APL204 study. Blood (ASH Annual Meeting Abstracts) 2012 ; 120 : Abstract 410
 
8) Diverio D et al : Early detection of relapse by prospective reverse transcriptasepolymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998 ; 92 : 784-9
 
9) de Botton S et al : Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid : a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005 ; 23 : 120-6
 
P.136 掲載の参考文献
1) Bennett JM et al : Proposals for the classification of the acute leukaemias. Br J Haematol 1976 ; 33 : 451-8
 
2) Swerdlow SH et al eds : WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, IARC Press, 2008
 
3) 竹内仁 : 急性リンパ性白血病 (Ph 染色体陽性急性リンパ性白血病を除く). 血液専門医テキスト, 日本血液学会 (編), 南江堂, 2011, p265-75
 
4) Rowe JM et al : Induction therapy for adults with acute lymphoblastic leukemia : results of more than 1500 patients from the international ALL trial : MRC UKALL XII/ECOG E2993. Blood 2005 ; 106 : 3760-7
 
5) Hayakawa F et al : Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute limphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J 2014 ; 4 : e252
 
6) Sebban C et al : Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission : a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994 ; 12 : 2580-7
 
7) Goldstone AH et al : In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients : final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008 ; 111 : 1827-33
 
8) 松田光弘ほか : 急性白血病. 日内会誌 2003 ; 92 : 969-78
 
9) Jinnai I et al : Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia : the JALSG-ALL97 study. Int J Hematol 2010 ; 92 : 490-502
PubMed
10) Takeuchi J et al : Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia 2002 ; 16 : 1259-66
 
11) Pui CH and Evans WE : Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 ; 354 : 166-78
 
12) Yanada M et al : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006 ; 24 : 460-6
 
13) Omura GA et al : Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980 ; 55 : 199-204
 
14) Thomas DA et al : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006 ; 106 : 1569-80
PubMed
15) Magrath I et al : Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996 ; 14 : 925-34
 
16) Hoelzer D et al : Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996 ; 87 : 495-508
 
17) Maruyama D et al : Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M) /ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010 ; 92 : 732-43
PubMed
P.146 掲載の参考文献
1) Vardiman JW et al : "Chronic myelogenous leukaemia, BCR-ABL1 positive". WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH et al eds, IARC Press, 2008, p32-7
 
2) O'Brien SG et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004
 
3) Deininger M et al : International Randomized Study of Interferon vs STI571 (IRIS) 8-Year Follow up : Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts) 2009 ; 114 : 1126
 
4) Druker BJ et al : Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 ; 355 : 2408-17
 
5) Kantarjian HM et al : Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012 ; 119 : 1123-9
 
6) Kantarjian HM et al : Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia : 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011 ; 12 : 841-51
 
7) 吉田近思 : 慢性骨髄性白血病. 臨床血液 2013 ; 54 : 61-70
 
8) Baccarani M et al : Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 ; 27 : 6041-51
 
9) Hughes TP et al : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003 ; 349 : 1423-32
 
10) 矢ケ崎史治ほか : Major bcr-abl mRNA定量におけるTMA法 (Amp-CML) とRealtime quantitative PCRの相関. 臨床血液 2009 ; 50 : 481-7
 
11) The Italian Cooperative Study Group on Chronic Myeloid Leukemia : Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994 ; 330 : 820-5
 
12) Silver RT et al : An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia : developed for the American Society of Hematology. Blood 1999 ; 94 : 1517-36
 
13) 松村到 : 慢性骨髄性白血病. 血液専門医テキスト, 日本血液学会 (編), 南江堂, 2011, p209-16
 
P.152 掲載の参考文献
1) British Committee for Standards in Haematology (BCSH) : Guideline on the diagnosis and management of chronic lymphocytic leukemia. Br J Haematol 2004 ; 125 : 294-317
 
2) Cheson BD et al : National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia : revised guidelines for diagnosis and treatment. Blood 1996 ; 87 : 4990-7
 
3) Kamihira S et al : Morphological and immunophenotypical characterization of Japanese B-cell lymphocytic leukemia. Leuk Lymphoma 1994 ; 16 : 113-9
 
4) Kipps TJ : Chronic lymphocytic leukemia and related disease. Williams Haematology, 7th ed, Lichtman MA et al eds, McGraw-Hill, 2006 ; p1343-83
 
5) Dohner H et al : Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 ; 343 : 1910-6
 
6) Rai KR et al : Clinical staging of chronic lymphocytic leukemia. Blood 1975 ; 46 : 219-34
 
7) Rai KR : A critical analysis of staging in CLL. Chronic lymphocytic leukemia : recent progress and future direction. UCLA Symposia on Molecular and Cellular Biology. Vol 59, Gale RP et al eds, Alan R Liss, New York, 1987, p253
 
8) Binet JL et al : A new prognostic classification of chronic lymphocytic leukemia derived from a multification survival analysis. Cancer 1981 ; 48 : 198-206
 
9) Wierde WG et al : Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007 ; 109 : 46-79
 
10) Hallek M et al : Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 ; 111 : 5446-56
 
11) 金倉譲 : CLLの新たな予後推定因子ZAP-70. Annual Review 血液 2005, 中外医学社, 2005, p190-9
 
12) Cheson BD : Therapy for previously untreated chronic lymphocytic leukemia : a reevaluation. Semin Hematol 1998 ; 35 : 14-21
 
P.161 掲載の参考文献
1) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, 2008
 
2) Carbone PP et al : Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971 ; 31 : 1860-1
 
3) Lister TA et al : Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol 1989 ; 7 : 1630-6
 
4) Hasenclever D et al : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998 ; 339 : 1506-14
 
5) Specht L et al : Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease : a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998 ; 16 : 830-43
 
6) Noordijk EM et al : Combined-modality therapy for clinical stage I and II Hodgkin's lymphoma : long-term results of the European Organization for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006 ; 24 : 3128-35
 
7) Engert A et al : Two cycles of doxorubicine, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma : final results of the GHSG HD7 trial. J Clin Oncol 2007 ; 25 : 3495-502
 
8) Cosser JM et al : The EORTC trials for limited stage Hodgkin's disease. The EORTC lymphoma Cooperative Group. Eur J Cancer 1992 ; 28A : 1847-50
 
9) Engert A et al : Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma : results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003 ; 21 : 3601-8
 
10) Cannellos PG et al : Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992 ; 327 : 1478-84
 
11) Diehl V et al : BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma : interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998 ; 16 : 3810-21
 
12) Diehl V et al : Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003 ; 348 : 2386-95
 
13) Borchmann P et al : Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma : final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011 ; 32 : 4234-42
PubMed
14) Steven M et al : Advances in the treatment of Hodgkin's lymphoma. Curr Opinion Hematol 2000 ; 7 : 235-40
 
15) Horning SJ et al : Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease : mature results of a prospective clinical trial. J Clin Oncol 2002 ; 20 : 630-7
 
16) Aleman BMP et al : Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003 ; 348 : 2396-406
 
17) Reece DE et al : Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994 ; 83 : 1193-9
 
18) Linch DC et al : Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease : results of a BNLI randomized trial. Lancet 1993 ; 341 : 1051-4
 
19) Peggs KS et al : Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005 ; 365 : 1906-8
 
20) Ogura M et al : Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Caner Sci 2014 ; 105 : 840-6
PubMed
P.185 掲載の参考文献
1) Jaffe ES et al eds : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, 2001
 
2) Hiddeman W et al : Lymphoma classification-the gap between biology and clinical management is closing. Blood 1996 ; 88 : 4085-9
 
3) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, 2008
 
4) The Non-Hodgkin's Lymphoma Pathologic Classification Project : National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas : summary and description of a working formulation for clinical usage. Cancer 1982 ; 49 : 2112-35
 
5) Harris NL et al : A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group. Blood 1994 ; 84 : 1361-92
 
6) The International Non-Hodgkin's Lymphoma Prognostic Factors Project : A predictive model for aggressive non-Hodgkin's lymphomas. N Engl J Med 1993 ; 329 : 987-94
 
7) Shipp MA et al : International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas : report of the jury. J Clin Oncol 1999 ; 17 : 423-9
 
8) Santini G et al : VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma : results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998 ; 16 : 2796-802
 
9) Haioun C et al : Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma : final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000 ; 18 : 3025-30
 
10) Strehl J et al : High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma : a meta-analysis. Hematologica 2003 ; 88 : 1304-15
 
11) Solal-Celigny P et al : Follicular lymphoma international prognostic index. Blood 2004 ; 104 : 1258-65
 
12) Miller TP et al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998 ; 339 : 21-6
 
13) Pfreundschuh M et al : CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011 ; 12 : 1013-22
 
14) Fisher RI et al : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993 ; 328 : 1002-6
PubMed
15) Feugier P et al : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 ; 23 : 4117-26
 
16) Pfreundschuh M et al : CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 ; 7 : 379-91
 
17) Habermann TM et al : Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 ; 24 : 3121-7
 
18) Tilly H et al : Intensive conventional chemotherapy (ACVBP regimen ) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003 ; 102 : 4284-9
 
19) Vitolo U et al : First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation : final results of an international phase II trial. J Clin Oncol 2011 ; 29 : 2766-72
 
20) Arkenau HT et al : The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007 ; 18 : 541-5
 
21) Gallamini A et al : Peripheral T-cell lymphoma unspecified (PTCL-U ) : a new prognostic model from a retrospective multicentric clinical study. Blood 2004 ; 103 : 2474-9
PubMed
22) Fisher RI et al : A clinical analysis of two indolent lymphoma entities : mantle cell lymphoma and marginal zone lymphoma : a Southwest Oncology Group study. Blood 1995 ; 85 : 1075-82
 
23) Lee J et al : Extranodal natural killer T-cell lymphoma, nasal-type : a prognostic model from a retrospective multicenter study. J Clin Oncol 2006 ; 24 : 612-8
 
24) Suzuki R et al : Prognostic factors for mature natural killer (NK ) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010 ; 21 : 1032-40
 
25) Federico M et al : R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma : results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013 ; 31 : 1506-13
 
26) Thomas DA et al : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006 ; 106 : 1569-80
PubMed
27) Magrath I et al : Adult and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996 ; 14 : 925-34
 
28) Mead GM et al : An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma : results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002 ; 13 : 1264-74
 
29) Lee EJ et al : Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia : results of Cancer and Leukemia Group B study 9251. J Clin Oncol 2001 ; 19 : 4014-22
PubMed
30) LaCasce A et al : Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas : preserved efficacy with decreased toxicity. Leuk Lymphoma 2004 ; 45 : 761-7
 
31) Dunleavy K et al : A prospective study of Dose-Adjusted (DA) EPOCH with rituximab in adult patients with newly diagnosed Burkitt lymphoma : A regimen with high efficacy and low toxicity. 10th International Conference on Malignant Lymphoma Abstracts. Ann Oncol 2008 ; 19 : iv83-4
 
32) Rohatiner A et al : Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994 ; 5 : 397-400
 
33) Nakamura S et al : Helicobacter pylori and primary gastric lymphoma. A histpathologic and immunohistochemical analysis of 237 patients. Cancer 1997 ; 79 : 3-11
 
34) Schechter NR et al : Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998 ; 16 : 1916-21
 
35) 大津敦 : 消化管悪性リンパ腫に対する非外科的治療の適応と有効性の評価に関する研究. 平成10年厚生労働省がん研究助成金による報告書, 1998, p425-56
 
36) Tanaka T et al : Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era : a multicenter study of 95 patients in Japan. Ann Hematol 2012 ; 91 : 383-90
 
37) Ferreri AJ et al : Prognostic scoring system for primary CNS lymphomas : the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003 ; 21 : 266-72
 
38) Ogura M et al : Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014 ; 32 : 1157-64
 
39) Pro B et al : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma : results of a phase II study. J Clin Oncol 2012 ; 30 : 2190-96
 
40) Tobinai K et al : Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2006 ; 24 : 174-80
 
41) Czuczman MS et al : Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005 ; 23 : 694-704
 
42) Forstpointner R et al : The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004 ; 104 : 3064-71
 
43) Robinson KS et al : Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008 ; 26 : 4473-9
PubMed
44) Rodriquez CO Jr et al : Arabinosylguanine-induced apoptosis of T-lymphoblastic cells : incorporation into DNA is a necessary step. Cancer Res 1999 ; 59 : 4937-43
 
45) Rummel MJ et al : Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicenter, randomized, phase 3 non-inferiority trial. Lancet 2013 ; 381 : 1203-10
PubMed
46) Flinn IW et al : Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL : the BRIGHT study. Blood 2014 ; 123 : 2944-52
 
47) Philip T et al : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995 ; 333 : 1540-5
 
48) Oki Y et al : Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 2008 ; 99 : 179-84
PubMed
49) Escalon MP et al : Nonmyeloablative allogeneic hematopoietic transplantation : a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004 ; 22 : 2419-23
 
50) Cheson BD et al : Revised response criteria for malignant lymphoma. J Clin Oncol 2007 ; 25 : 579-86
 
51) Yamaguchi M et al : De novo CD5+ diffuse large B-cell lymphoma : a clinicopathologic study of 109 patients. Blood 2002 ; 99 : 815-21
 
52) Rosenwald A et al : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002 ; 346 : 1937-47
 
53) Hans CP et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 ; 103 : 275-82
 
P.201 掲載の参考文献
1) Katzmann JA et al : Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains : relative sensitivity for detection of monoclonal light chains. Clin Chem 2002 ; 48 : 1437-44
 
2) Bradwell AR : Serum free light chain analysis (plus Heavylite), 5th ed, The Biding Site Ltd, 2008
 
3) International Myeloma Working Group : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol 2003 ; 121 : 749-57
 
4) Fujii R et al : MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999 ; 105 : 131-40
 
5) Avet-Loiseau H et al : Oncogenesis of multiple myeloma : 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002 ; 99 : 2185-91
PubMed
6) Mateos MV et al : Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma : updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010 ; 28 : 2259-66
 
7) 日本骨髄腫研究会 (編) : 多発性骨髄腫の診療指針 第3版, 文光堂, 2012
 
8) Greipp PR et al : International staging system for multiple myeloma. J CIin Oncol 2005 ; 23 : 3412-20
 
9) Durie BGM et al : International uniform response criteria for multiple myeloma. Leukemia 2006 ; 20 : 1467-73
 
10) Moreau P et al : Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma : a randomised, phase 3, non-inferiority study. Lancet Oncol 2011 ; 12 : 431-40
 
11) Dimopoulos MA et al : Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004 ; 117 : 508-15
 
12) Attal M et al : Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006 ; 108 : 3289-94
 
13) Spencer A et al : Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Ciln Oncol 2009 ; 27 : 1788-93
 
14) McCarthy PL et al : Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 ; 366 : 1770-81
 
15) Pulumbo A et al : Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012 ; 366 : 1759-69
 
16) 清水一之 : 多発性骨髄腫における二次性 (治療関連) 原発性悪性腫瘍-13th IMW2011 Paris での報告-. 日本骨髄腫研究会誌 2011 ; 1 : 67-72
 
17) Berenson JR et al : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996 ; 334 : 488-93
 
18) Henry DH et al : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Ciln Oncol 2011 ; 29 : 1125-32
PubMed
19) 日本骨髄腫研究会 (編) : 多発性骨髄腫の診療指針第2版, 文光堂, 2008, p71-85
 
20) San-Miguel JF et al : Efficacy and safety of bortezomib in patients with renal impairment : results from the APEX phase 3 study. Leukemia 2008 ; 22 : 842-9
 
21) Smith A et al : Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005 ; 132 : 410-51
 
P.209 掲載の参考文献
1) 再生不良性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ : 再生不良性貧血 診療の参照ガイド (平成22年度改訂版), 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 特発性造血障害に関する調査研究, 2011 (http://zoketsushogaihan.com/file/AA.pdf)
 
2) Appelbaum FR et al : Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987 ; 15 : 1134-39
 
3) Sugimori C et al : Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006 ; 107 : 1308-14
 
4) Frickhofen N et al : Antithymocyte globulin with or without cyclosporin A : 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003 ; 101 : 1236-42
 
5) British Committee for Standards in Haematology : Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009 ; 147 : 43-70
 
6) Gurion R et al : Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009 ; 94 : 712-9
 
7) Schrezenmeier H et al : Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007 ; 110 : 1397-1400
 
8) Socie G et al : Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993 ; 329 : 1152-7
PubMed
P.213 掲載の参考文献
1) Fisch P et al : Pure red cell aplasia. Br J Haematol 2000 ; 111 : 1010-22
 
2) 赤芽球癆診療の参照ガイド改訂版作成のためのワーキンググループ : 赤芽球癆診療の参照ガイド (平成22年度改訂版), 2011 (http://zoketsushogaihan.com/file/PRCA.pdf)
 
3) Mamiya S et al : Acquired pure red cell aplasia in Japan. Eur J Haematol 1997 ; 59 : 199-205
 
4) Crabol Y et al : Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection : a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013 ; 56 : 968-77
 
P.228 掲載の参考文献
1) Bennett JM et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 ; 51 : 189-99
 
2) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, 2008, p88-93
 
3) 不応性貧血 (骨髄異形成症候群) の診断基準と診療の参照ガイド改定版作成のためのワーキンググループ : 不応性貧血 (骨髄異形成症候群) 診療参照ガイド (平成22年度改訂版). 小澤敬也 (編), 2011, p57-98
 
4) Van den Berghe H et al : Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974 ; 251 : 437
PubMed
5) Bennett JM et al : The chronic myeloid leukemias : guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposal by the French-American-British Cooperative Leukemia Group. Br J Haematol 1994 ; 87 : 746-54
 
6) 伊藤雅文 : MDSの骨髄病理組織. 骨髄異形成症候群 (MDS) 診療up-to-date, 松田晃 (編), 中外医学社, 2012, p35-47
 
7) Greenberg P et al : International scoring system for evaluating prognosis in myelodisplastic syndromes. Blood 1997 ; 89 : 2079-88
 
8) Greenberg PL et al : Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood 2012 ; 120 : 2454-65
 
9) Peter L et al : Myelodysplastic syndromes, version 2. 2015. JNCCN 2015 ; 13 : 261-272
 
10) Rose C et al : Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010 ; 34 : 864-70
 
11) 小澤敬也ほか : 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 特発性造血障害に関する調査研究班 (平成20年度), 2009
 
12) Hellstrom-Lindberg E : Efficacy of erythropoietin in the myelodysplastic syndromes. A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995 ; 89 : 67-71
 
13) Yoshida Y et al : A phase II trials of recombinant human granulocyte colony stimulating factor in the myelodysplastic syndrome. Br J Haematol 1991 ; 78 : 378-84
 
14) Wang H et al : Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002 ; 100 : 3897-902
 
15) List A et al : Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005 ; 352 : 549
PubMed
16) List A et al : lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 ; 355 : 1456
PubMed
17) Raza A et al : Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008 ; 111 : 86
PubMed
18) Silverman LR et al : Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the Cancer and Leukemia Group B. J Clin Oncol 2002 ; 20 : 2429
 
19) Ohno R et al : Treatment of myelodysplastic syndromes with orally administerd 1-β-D-arabinofuranosylcytosine-5?-stearylphosphate. Oncology 1991 ; 48 : 451-5
 
P.235 掲載の参考文献
1) 大野良之 : 「特定疾患治療研究事業未対象疾患の疫学像を把握するための調査研究班」平成11年度研究業績集-最終報告書-, 2000
 
2) Hillmen P et al : Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 ; 110 : 4123-28
 
3) Nishimura J et al : Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 2004 ; 83 : 193-207
 
4) Roth A et al : Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur J Haematol 2011 ; 87 : 473-9
 
5) Takeda J et al : Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993 ; 73 : 703-11
 
6) Maciejewski JP et al : Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood 1997 ; 89 : 1173-81
PubMed
7) Van Bijnen ST et al : Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012 ; 10 : 1-10
PubMed
8) Sugimori C et al : Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006 ; 107 : 1308-14
 
9) Ishikawa T et al : A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome : presence of CD55-CD59- blood cells predicts platelet response. Int J Hematol 2007 ; 86 : 150-7
 
10) 黒川峰夫ほか : 発作性夜間ヘモグロビン尿症診療の参照ガイド (平成26年度改訂版). 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 特発性造血障害に関する調査研究, 2015
 
11) Kawahara K et al : Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol 1992 ; 39 : 283-8
PubMed
12) Kanakura Y et al : Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS clinical trial. Int J Hematol 2011 ; 93 : 36-46
 
13) Parker C et al : International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005 ; 106 : 3699-709
 
14) Rosse WF : Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982 ; 60 : 20-3
 
15) Brecher ME et al : Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited. Transfusion 1989 ; 29 : 681-5
PubMed
16) Dunn D et al : Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999 ; 131 : 401-8
 
P.249 掲載の参考文献
1) 小峰光博 : 免疫性溶血性貧血. 三輪血液病学, 浅野茂隆ほか (監), 文光堂, 2006, p1181-227
 
2) 厚生労働省 特発性造血障害に関する調査研究班 : 自己免疫性溶血性貧血. 特発性造血障害疾患の診療の参照ガイド (平成22年度改訂版), 小澤敬也 (編), 2011
 
3) Gaziev J et al : Stem cell transplantation and gene therapy for hemoglobinopathies. Curr Hematol Rep 2005 ; 4 : 126-31
 
4) Durieu I et al : Efficacy and safety of rituximab in auto-immune hemolytic anemia : A meta-analysis of 21 studies. Autoimmun Rev 2015 ; 14 : 304-13
PubMed
P.254 掲載の参考文献
1) Beutler E : Disorders of iron metabolism. Williams Hematology, 8th ed, Kaushansky K et al eds, McGraw-Hill, 2010, p565-606
 
P.260 掲載の参考文献
1) Green R : Folate, cobalamin, and megaloblastic anemias. Williams Hematology, 8th ed, Kaushansky K et al eds, McGraw-Hill, 2010, p533-63
 
2) Nyholm E et al : Oral vitamin B12 can change our practice. Postgrad Med J 2003 ; 79 : 218-20
 
P.274 掲載の参考文献
1) Kuwana M et al : Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura : evaluation by multi-center prospective study. J Thromb Haemost 2006 ; 4 : 1936-43
 
2) Koike Y et al : Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentration. Thromb Haemost 1998 ; 79 : 1106-10
 
3) 藤村欣吾ほか : 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 2012 ; 53 : 433-42
 
4) Fujimura K et al : Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005 ; 81 : 162-8
 
5) 蔵本淳ほか : ITP合併妊娠における母親の出血管理 (アンケート調査報告). 厚生省特定疾患特発性造血障害調査研究班 平成6年度研究業績報告書, 1995, p203-7
 
6) George JN et al : Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 ; 88 : 3-34
 
7) McMillan R : Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Int Med 1997 ; 126 : 307-14
PubMed
8) British Committee for Standards in Haematology General Haematology Task Force : Guideline for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003 ; 120 : 574-96
 
9) Vesely SK et al : Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy : a systematic review. Ann Intern Med 2004 ; 140 : 112-20
PubMed
10) Stasi R et al : Idiopathic thrombocytopenic purpura : current concepts in pathophysiology and management. Thromb Haemost 2008 ; 99 : 4-13
 
11) van Staa TP et al : The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int 2002 ; 13 : 777-87
 
12) Nawata H et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005 ; 23 : 105-9
 
13) Lagares FM et al : Complete splenic embolization in the treatment of immune thrombocytopenic purpura. Br J Haematol 1998 ; 103 : 894-5
 
14) Caulier MT et al : Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra-indications to splenectomy. Br J Haematol 1995 ; 91 : 208-11
 
15) Kojouri K et al : Splenectomy for adult patients with idiopathic thrombocytopenic purpura : A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004 ; 104 : 2623-34
 
16) McMillan R et al : Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004 ; 104 : 956-60
PubMed
17) Friedman RL et al : Laparoscopic or open splenectomy for hematologic disease-Which approach is superior? J Am Coll Surg 1997 ; 185 : 49-54
 
18) Torelli P et al : Laparoscopic splenectomy for hematological diseases. Surg Endosc 2002 ; 16 : 965-71
 
P.284 掲載の参考文献
1) Levi M et al : Disseminated intravascular coagulation. N Engl J Med 1999 ; 341 : 586-92
 
2) Taylor FB Jr et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001 ; 86 : 1327-30
 
3) Levi M et al : Disseminated intravascular coagulation. Williams Haematology, 8th ed, Kanshansky K et al eds, McGraw-Hill, 2010, p2101-20
 
4) 吉田秀ほか : 間違いやすいDICマーカーの読み. 臨床医 1999 ; 25 : 623-7
 
5) Rangel-Frausto MS et al : The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995 ; 273 : 117-23
 
6) Vincent JL et al : The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996 ; 22 : 707-10
 
7) Gando S et al : Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005 ; 11 : 71-6
 
8) 松田保 : DICの成因疾患に関するアンケート調査の結果について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度研究報告書, 1993, p17-23
 
9) Okajima K et al : Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am J Hematol 1996 ; 51 : 186-91
 
10) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 2009 ; 20 : 77-113
 
11) Sakuragawa N et al : Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) -a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 1993 ; 72 : 475-500
 
12) Warren BL et al : High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 2001 ; 286 : 1869-78
 
13) Kienast J et al : Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 ; 4 : 90-7
 
P.291 掲載の参考文献
1) Furlan M et al : Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. New Engl J Med 1998 ; 339 : 1578-84
 
2) Tsai H et al : Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New Engl J Med 1998 ; 339 : 1585-94
 
3) Galbusera M et al : Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. Blood 1999 ; 94 : 610-20
 
4) 藤村吉博 : adamts13-TMAの診断と血小板輸血の重要指標. 日本血栓止血学会誌 2006 ; 17 : 144-62
 
5) von der Plas RM et al : von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999 ; 93 : 3798-802
 
6) Remuzzi G et al : Thrombotic microangiopathies including hemolytic uremic syndrome. Johnson & Feehally's Comprehensive Clinical Nephrology, Mosby, 2000, p33.1-33.12
 
7) Ring GH et al : Microvascular diseases of the kidney. Brenner & Rector's The Kidney, 6th ed, WB Saunders, 2000, p1597-603
 
P.296 掲載の参考文献
1) Ortel TL : Heparin-induced thrombocytopenia : when a low platelet count is a mandate for anticoagulation. Hematology Am Soc Hematol Educ Program 2009 ; 2009 : 225-32
 
2) Miyakis S et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306
 
3) 難病情報センター : 抗リン脂質抗体症候群 (http://www.nanbyou.or.jp/entry/261)
 
4) Pengo V et al : Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009 : 7 : 1737-40
 
5) 家子正裕 : 抗リン脂質抗体症候群の診断と治療. 臨床血液 2014 ; 55 : 917-24
 
6) 家子正裕 : 後天性血液凝固制御異常に伴う血栓症-とくに抗リン脂質抗体症候群 (APS) 医学のあゆみ 2012 ; 242 : 181-7
 
7) 渥美達也 : 抗リン脂質抗体症候群のマネージメント. 臨床血液 2010 ; 50 : 103-9
 
8) 山崎雅英 : 抗リン脂質抗体症候群の治療. 日本血栓止血学会誌 2008 ; 19 : 333-5
 
9) 阿部達生 (監) : 血液疾患 (New専門医を目指すケース・メソッド・アプローチ) 第2版, 日本医事新報社, 2012, p310-20
 
P.301 掲載の参考文献
1) Ansell JE : Managing oral anticoagulant therapy : optimizing patient outcomes. American Society of Hematology Education Program Book, 2000, p275-84
 
2) HIT情報センターホームページ (http://www.hit-center.jp/)
 
3) Heparin-Induced Thrombocytopenia, 4th ed, Warkentin TE eds, CRC Press, 2007
 
4) Rost S et al : Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004 ; 427 : 537-41
 
5) Rieder MJ et al : Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 ; 352 : 2285-93
 
6) Aithal GP et al : Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999 ; 353 : 717-9
PubMed
P.310 掲載の参考文献
1) 公益財団法人エイズ予防財団 : 血液凝固異常症全国調査平成25 年度報告書, 2013
 
2) Nichols WC et al : Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998 ; 93 : 61-70
 
3) 嶋緑倫ほか : 第VIII因子欠乏症 (血友病A). 小児慢性特定疾患治療マニュアル, 柳沢正義ほか (編), 診断と治療社, 1999, p442-6
 
4) Castaman G : New development in von Willebrand disease. Curr Opin Hematol 2013 ; 20 : 424-9
 
P.318 掲載の参考文献
1) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, 2008
 
2) Tefferi A : Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms : JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010 ; 24 : 1128-38
 
3) Levine RL et al : Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 ; 7 : 387-97
 
4) Dan K et al : Clinical features of polycythemia vera and essential thrombocythemia in Japan : retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol 2006 ; 83 : 443-9
 
5) 小峰光博ほか : 骨髄線維症の診断基準と診療の参照ガイド作成のためのワーキンググループ : 骨髄線維症診療の参照ガイド. 臨床血液 2006 ; 47 : 662-77
 
6) Vardiman JW et al : The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia : rationale and important changes. Blood 2009 ; 114 : 937-51
 
7) Marchioli R et al : Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005 ; 23 : 2224-32
 
8) Elliott MA et al : Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005 ; 128 : 275-90
 
9) Tefferi A : Polycythemia vera and essential thrombocythemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012 ; 87 : 285-93
 
10) Michiels JJ et al : The paradox of platelet activation and impaired function : platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006 ; 32 : 589-604
 
11) Barosi G et al : A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia : results of a consensus process by an international working group. Leukemia 2007 ; 21 : 277-80
 
12) Barbui T et al : Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis : an international study. J Clin Oncol 2011 ; 29 : 3179-84
 
13) Crisa E et al : A retrospective study on 226 polycythemia vera patients : impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and nonalkylating drugs. Ann Hematol 2010 ; 89 : 691-9
 
14) Finazzi G et al : Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 2008 ; 22 : 1494-502
 
15) Barbui T et al : Myeloproliferative disease in pregnancy and other management issues. Hematology Am Soc Hematol Educ Program 2006 ; 246-52
 
16) Passamonti F et al : Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (V617F) mutation. Blood 2007 ; 110 : 485-9
 
17) Ruggeri M et al : Thrombotic and hemorrhagic complications after surgery in patients with essential thrombocythemia and polycythemia vera [abstract]. Blood 2006 ; 108 : 761, Abstract 2693
 
18) Cervantes F et al : New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009 ; 113 : 2895-901
 
19) Tefferi A : How I treat myelofibrosis. Blood 2011 ; 117 : 3494-504
 
20) 泉二登志子 : 骨髄増殖性腫瘍の治療. 臨床血液 2010 ; 51 : 108-16
 
21) Tefferi A et al : Lenalidomide therapy in del (5) (q31) -associated myelofibrosis : cytogenetic and JAK2V617F molecular remissions. Leukemia 2007 ; 21 : 1827-8
PubMed
22) Vannucchi AM : Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011 : 222-30
 
23) Patriarca F et al : Allogeneic hematopoietic stem cell transplantation in myelofibrosis : the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008 ; 93 : 1514-22
 
24) Stewart WA et al : The role of allogeneic SCT in primary myelofibrosis : a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010 ; 45 : 1587-93
 
P.326 掲載の参考文献
1) 熊倉俊一 : HPS の病態・診断・治療. 日本血栓止血学会誌 2008 ; 19 : 210-5
 
2) Ishii E et al : Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007 ; 86 : 58-65
 
3) 高橋直人 : 血球貪食症候群. 血液疾患最新の治療 2011-2013, 直江知樹ほか (編), 南江堂, 2010, p246-9
 
4) 今宿晋作 : 血球貪食症候群とは. 血液・腫瘍科 1996 ; 3 : 433
 
5) Henter JI et al : HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer 2007 ; 48 : 124-31
 
P.328 掲載の参考文献
1) 菊池昌弘 : 特異な組織像を呈するリンパ節炎について. 日血会誌 1972 ; 35 : 379-80
 
2) 菊池昌弘ほか : 組織球性壊死性リンパ節炎 (菊池, 藤本病). 病理と臨床 1994 ; 12 : 375-8
 
3) Kikuchi M : Viral lesions in lymph nodes. Surgical Pathology, Update 2001, Hauptmann S et al eds, ABW Wissenschaftsverlag, 2001, p406-9
 
P.332 掲載の参考文献
1) 日本造血細胞移植学会, 日本輸血・細胞治療学会 : 造血細胞移植-同種末梢血幹細胞移植のための健常人ドナーからの末梢血幹細胞動員・採取に関するガイドライン (http://www.jshct.com/guideline/allo_pbsct_guide.shtml)
 
2) Remberger M et al : No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cell to bone marrow using unrelated donors. Blood 2001 ; 98 : 1739-45
 
3) Eapen M et al : Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents : the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004 ; 22 : 4872-80
PubMed
4) Murata M et al : peripheral blood stem cell mobilization and apheresis : analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999 ; 24 : 1065-71
PubMed
5) Takahashi S et al : Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004 ; 104 : 3813-20
 
P.346 掲載の参考文献
1) Michael M et al : Nonmyeloablative hematopoietic stem cell transplantation : transplantation for the 21 century. Front Biosci 2001 ; 6 : 13-6
 
2) Thomas ED et al : Bone marrow transplantation. N Engl J Med 1975 ; 292 : 832-43
 
3) Thomas ED et al : Bone marrow transplantation. N Engl J Med 1975 ; 292 : 895-902
 
4) 幸道秀樹 : 慢性GVHD. 領域別症候群シリーズ 血液症候群 III, 日本臨牀社, 1998, p601-4
 
P.351 掲載の参考文献
1) Magni M et al : Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma : evidence for a role of both chemotherapy and rituximab infusion. Blood 2000 ; 96 : 864-9
 

IV. 化学療法中の支持療法

P.355 掲載の参考文献
1) Howard SC et al : The tumor lysis syndrome. N Engl J Med 2011 ; 364 : 1844-54
 
2) Will A et al : The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011 ; 154 : 3-13
 
3) Lopez-Olivo MA et al : Rasburicase in tumor lysis syndrome of the adult : a systematic review and meta-analysis. Am J Kidney Dis 2013 ; 62 : 481-92
 
P.360 掲載の参考文献
1) 吉田清一 (監) : 癌化学療法の副作用対策改訂版, 先端医学社, 1996
 
2) Appelbaum TR et al : Hematology 1996 Education Program, American Society of Hematology, 1996, p33-47
 
3) Sonis ST : Regimen-related gastrointestinal toxicities in cancer patients. Curr Opin Support Palliat Care 2010 ; 4 : 26-30
 
4) 日本癌治療学会 (編) : 制吐薬適正使用ガイドライン 第1版, 金原出版, 2010
 
P.364 掲載の参考文献
1) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂, 2012
 
2) Freifeld AG et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of America. Clin Infect Dis 2011 ; 52 : e56
 
3) Gafter-Gvili A et al : Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012 ; 1 : CD004386
PubMed
4) Cruciani M et al : Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003 ; 21 : 4127-37
PubMed
5) Worth LJ et al : An analysis of the utilization of chemoprophylaxis against Pneumocystis jiroveci pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005 ; 92 : 867-72
 
6) 深在性真菌症のガイドライン作成委員会 (編) : 深在性真菌症の診断・治療ガイドライン 2014, 協和企画, 2014
 
7) 日本医真菌学会 : 侵襲性カンジダ症の診断・治療ガイドライン 2013
 
8) Schwartz S et al : Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia : results of a prospective randomized multicenter trial. Blood 1999 ; 93 : 3654-61
 
9) Kume H et al : Epidemiology of visceral mycoses in autopsy cases in Japan : comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J 2011 ; 52 : 117-27
 
10) Togano T et al : Estimated numbers of visceral mycoses in case of leukemia and MDS in Japan. Med Mycol J 53 : 53-58, 2012
PubMed
11) Suzuki Y et al : Epidemiology of visceral mycoses in autopsy cases in Japan : the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan. Med Mycol 2013 ; 51 : 522-6
 
12) 日本肝臓学会 (編) : B型肝炎治療ガイドライン (第2.1版), 2015
 
P.370 掲載の参考文献
1) CDC : Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients, 2001 (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm)
 
2) 日本造血細胞移植学会 (編) : 造血細胞移植ガイドライン 移植後早期の感染管理 第2版, 2012 (http://www.jshct.com/guideline/pdf/kansenkanri.pdf)
 
3) CDC : Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011, 2011 (http://www.cdc.gov/hicpac/PDF/guidelines/bsi-guidelines-2011.PDF)
 
4) CDC : 2007 Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Healthcare Settings, 2007 (http://www.cdc.gov/hicpac/PDF/isolation/isolation2007.PDF)
 
P.376 掲載の参考文献
1) 厚生労働省 : 重篤副作用疾患別対応マニュアル 薬物性肝障害, 2008 (http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1i01.pdf)
 
2) 滝川一ほか : DDW-J2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 2005 ; 46 : 85-90
 
3) Watanabe M et al : Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation : a review of 16 patients. Eur J Intern Med 2010 ; 21 : 333-7
 
4) Watanabe M et al : Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int 2011 ; 31 : 340-7
PubMed
5) 日本肝臓学会肝炎診療ガイドライン作成委員会 (編) : B型肝炎治療ガイドライン 第2.1版 (http://www.jsh.or.jp/medical/guidelines/jsh_guidelines/hepatitis_b)
 

V. 治療による合併症, 処置中のトラブルへの対応

P.379 掲載の参考文献
1) Larson DL : Treatment of tissue extravasation by antitumor agents. Cancer 1982 ; 49 : 1796-9
PubMed
2) Bellone JD : Treatment of vincristine extravasation. JAMA 1981 ; 245 : 343
PubMed
3) Mullin S et al : Prevention and management of injury of antineoplastic extravasation. Hosp Pharm 2000 ; 35 : 57-74
 
4) Kane RC et al : Dexrazoxane (Totect) : FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist 2008 ; 13 : 445-50
 
P.384 掲載の参考文献
1) Bone RC et al : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992 ; 101 : 1644-55
 
2) Vasu TS et al : Norepinephrine or dopamine for septic shock : systematic review of randomized clinical trials. J Intensive Care Med 2012 ; 27 : 172-8
PubMed
3) Lefering R et al : Steroid controversy in sepsis and septic shock : a meta-analysis. Crit Care Med 1995 ; 23 : 1294-303
 
P.391 掲載の参考文献
1) Schrier RW et al : Renal and Electrolyte Disorders, 7th ed, Lippincott Williams & Wilkins, 2010, p1-74
 
2) Narins RG : Maxwell & Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed, McGraw-Hill, 1994
 
P.403 掲載の参考文献
1) Vardiman JW et al : Therapy-related myeloid neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH et al eds, IARC Press, 2008, p128
 
2) Smith SM et al : Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia : the University of Chicago series. Blood 2003 ; 102 : 43-52
 
3) Brusamolino E et al : The risk of therapy-related myelodysplasia/acute myeloid leukemia in Hodgkin lymphoma has substantially decreased in the ABVD era abolishing mechlorethamine and procarbazine and limiting volumes and doses of radiotherapy. Mediterr J Hematol Infect Dis 2012 ; 4 : e2012022
PubMed
4) 宮崎泰司 : 二次性 (治療関連) 白血病. 血液専門医テキスト, 日本血液学会 (編), 南江堂, 2011, p261-4
 
5) Singh ZN et al : Therapy-related myelodysplastic syndrome : morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007 ; 127 : 197-205
PubMed

VI. 補助療法

P.411 掲載の参考文献
1) Klastersky J et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000 ; 18 : 3038-51
PubMed
2) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂, 2012
 
3) 青木眞 : レジデントのための感染症診療マニュアル 第2版, 医学書院, 2007
 
P.414 掲載の参考文献
1) Cazzola M et al : Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997 ; 89 : 4248-67
 
2) Hellstrom-Lindberg E : Efficacy of erythropoietin in the myelodysplastic syndromes : a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995 ; 89 : 67-71
 
P.421 掲載の参考文献
1) 厚生労働省医薬食品局血液対策課 : 「輸血療法の実施に関する指針」 (改定版), 2012 (http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/dl/tekisei-01.pdf)
 
2) 厚生労働省医薬食品局血液対策課 : 「血液製剤の使用指針」 (改定版), 2012 (http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/dl/tekisei-02.pdf)
 
3) 東京都福祉保健局 : 輸血療法など特定生物由来製品による治療についての説明書. 輸血療法の手引き (第3版), 2010 (http://www.fukushihoken.metro.tokyo.jp/iryo/k_isyoku/tebiki.files/yuketsu.p48-49.pdf)
 
4) 東京都福祉保健局 : 輸血同意書. 輸血療法の手引き (第3版), 2010 (http://www.fukushihoken.metro.tokyo.jp/iryo/k_isyoku/tebiki.files/yuketsu.p50.pdf)
 
5) 日本輸血・細胞治療学会 : 「血液製剤使用時の説明と同意書」「輸血後感染症検査のお知らせ」に関する書式例 (http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/reference/Ref17-1.pdf)
 
6) 厚生労働省特発性造血障害に関する調査研究班 (平成20年度, 研究代表者 : 小澤敬也) : 輸血後鉄過剰症の診療ガイド (http://www.jichi.ac.jp/zoketsushogaihan/tetsufinal.pdf)
 
7) Gaydos LA et al : The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962 ; 266 : 905-9
 
8) Rebulla P et al : The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997 ; 337 : 1870-5
PubMed
9) Sagmeister M et al : A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999 ; 93 : 3124-6
PubMed
10) The Trial to Reduce Alloimmunization to Platelets Study Group : Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997 ; 337 : 1861-9
 
11) 日本輸血・細胞治療学会 : 輸血実施手順, 2001 (http://yuketsu.jstmct.or.jp/wpcontent/themes/jstmct/images/medical/file/reference/Ref11-1.gif), (http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/reference/Ref11-2.gif)
 
12) 日本輸血・細胞治療学会 : ABO不適合輸血時の治療指針 (http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/reference/Ref11-4.pdf)
 
P.424 掲載の参考文献
1) Narins RG : Maxwell & Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism, 5th ed, McGraw-Hill, 1994
 
2) 鎌田貢壽ほか : 腎不全患者の輸液. 輸液療法, 稲田 豊ほか (編), 金原出版, 1988, p209-22
 
P.434 掲載の参考文献
1) 高宮有介 : がんの痛みのアセスメントの実際. がん看護 2003 ; 8 : 21-5
 
2) 日本緩和医療学会 (編) : がん疼痛治療ガイドライン, 金原出版, 東京, 2010
 
3) 世界保健機関 (編), 武田文和 (訳) : がんの痛みからの解放・WHO方式がん疼痛治療法 第2版, 金原出版, 1996
 
4) 国立がんセンター中央病院薬剤部 : オピオイドによるがん疼痛緩和 改訂版, エルゼビア・ジャパン, 2012
 
5) 淀川キリスト教病院ホスピス (編) : 緩和ケアマニュアル 第5版, 最新医学社, 2007
 
6) 東原正明 (編) : 癌緩和ケア, 新興医学出版社, 2008
 
7) 聖隷三方原病院 : 症状緩和ガイド (http://www.seirei.or.jp/mikatahara/doc_kanwa/)
 
P.438 掲載の参考文献
1) Mortimer JE et al : Medical management of malignant disease. The Washington Manual of Medical Therapeutics, 34th ed, Cooper DH et al eds, LWW, 2013
 
2) Ferreri AJ : How I treat primary CNS lymphoma. Blood 2011 ; 118 : 510-22
 
3) Wilson LD et al : Superior vena cava syndrome with malignant causes. N Engl J Med 2007 ; 356 : 1862-9
 
4) Hochloch K : Superior vena cava syndrome caused by a malignant tumor : a retrospective single-center analysis of 124 cases. J Cancer Res Clin Oncol 2014 ; 140 : 2129-34
 

VII. インフォームドコンセントに必要な治療成績, 統計

P.444 掲載の参考文献
1) Miyawaki S : Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. Int J Hematol 2012 ; 96 : 171-7
 
2) Ohno R : How high can we increase complete remission rate in adult acute myeloid leukemia? Int J Hematol 2000 ; 72 : 272-9
 
3) Asou N et al : A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy : The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007 ; 110 : 59-66
 
4) Shinagawa K et al : A phase III study of new synthetic retinoid Tamibarotene (Am80) compared with ATRA in maintenance therapy for newly diagnosed acute promyelocytic leukemia (APL) : Japan Adult Leukemia Study Group (JALSG) APL204 Study. Blood (ASH Annual Meeting Abstracts) 2012 ; 120 : Abstract 410
 
5) 日本造血細胞移植学会データセンター : 日本造血細胞移植学会平成24年度全国調査報告書, 2013, p92-151
 
6) Zittoun RA et al : Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995 ; 332 : 217-23
 
7) Cassileth PA et al : Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1996 ; 339 : 1649-56
 
8) Pui CH et al : Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 ; 354 : 166-78
 
9) Jinnai I et al : Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia : the JALSG-ALL97 study. Int J Hematol 2010 ; 92 : 490-502
PubMed
10) Thiebaut A et al : Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. Hemtol Oncol Clin North Am 2000 ; 14 : 1353-66
 
11) Sebban C et al : Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission : a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994 ; 12 : 2580-7
 
P.450 掲載の参考文献
1) Sokal JE et al : Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984 ; 63 : 789-99
 
2) O'Brien SG et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 ; 348 : 994-1004
 
3) Druker BJ et al : Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 ; 355 : 2408-17
 
4) Deininger M et al : International Randomized Study of Interferon vs STI571 (IRIS) 8-Year Follow up : Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts) 2009 ; 114 : 1126
 
5) Kantarjian HM et al : Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012 ; 119 : 1123-9
 
6) Kantarjian HM et al : Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia : 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011 ; 12 : 841-51
 
7) Talpaz M et al : Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987 ; 69 : 1280-8
 
8) The Italian Cooperative Study Group on Chronic Myeloid Leukemia : Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994 ; 330 : 820-5
 
9) 日本造血細胞移植学会データセンター : 日本造血細胞移植学会平成24年度全国調査報告書, 2013, p152-166
 
10) Gratwohl A et al : Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998 ; 352 : 1087-92
 
P.454 掲載の参考文献
1) Hasenclever D et al : A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998 ; 339 : 1506-14
 
2) Solal-Celigny P et al : Follicular lymphoma international prognostic index. Blood 2004 ; 104 : 1258-65
 
3) The International Non-Hodgkin's Lymphoma Prognostic Factors Project : A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 ; 329 : 987-94
 
4) Coiffier B et al : Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010 ; 116 : 2040-5
 
5) Wierda WG et al : Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007 ; 109 : 4679-85
 
P.457 掲載の参考文献
1) Kumar SK et al : Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 ; 111 : 2516-20
 
2) San Miguel JF et al : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 ; 359 : 906-17
 
3) Attal M et al : A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996 ; 335 : 91-7
 
4) Lenhoff S et al : Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Blood 2000 ; 95 : 7-11
PubMed
5) McCarthy PL et al : Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 ; 366 : 1770-81
 
6) Bjorkstrand B et al : European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001 ; 38 : 219-25
 
7) 日本造血細胞移植学会データセンター (編) : 日本造血細胞移植学会平成24年度全国調査報告書, 2013
 
P.464 掲載の参考文献
1) 日本造血細胞移植学会データセンター : 日本造血細胞移植学会平成24年度全国調査報告書, 2013, p222-4
 
2) Scheinberg P : Aplastic anemia : therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012 ; 2012 : 292-300
 
3) Frickhofen N et al : Antithymocyte globulin with or without cyclosporin A : 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003 ; 101 : 1236-42
 
4) Rosenfeld SJ et al : Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995 ; 85 : 3058-65
 
5) 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 特発性造血障害に関する調査研究班 : 再生不良性貧血. 特発性造血障害疾患の診療の参照ガイド 平成22年度改訂版. 小澤敬也 (編), 2011 (http://zoketsushogaihan.com/file/AA.pdf)
 
6) Zheng Y et al : Immunosuppressive therapy for acquired severe aplastic anemia (SAA) : a prospective comparison of four different regimens. Exp Hematol 2006 ; 34 : 826-31
 
7) Atta EH et al : Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia : a single-center retrospective study. Ann Hematol 2010 ; 89 : 851-9
PubMed
8) Afable MG 2nd et al : Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011 ; 96 : 1269-75
 
9) Scheinberg P et al : Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011 ; 365 : 430-8
 
10) Marsh JC et al : Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012 ; 119 : 5391-6
PubMed
11) Greenberg P et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 ; 89 : 2079-88
 
12) Kantarjian H et al : Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006 ; 106 : 1099-109
 
13) Morita Y et al : Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol 2010 ; 91 : 97-103
 
14) Fenaux P et al : Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991 ; 77 : 497-501
 
15) de Witte T et al : Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995 ; 9 : 1805-11
PubMed
16) Gore SD et al : Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy. Blood 1995 ; 86 : 339a
 
17) Bernstein SH et al : Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria : a Cancer and Leukemia Group B Study. J Clin Oncol 1996 ; 14 : 2486-94
 
18) Ruutu T et al : Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997 ; 21 : 133-8
PubMed
19) Wattel E et al : Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy : incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997 ; 98 : 983-91
 
20) Estey E et al : Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997 ; 90 : 2969-77
 
21) Bernasconi C et al : Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998 ; 102 : 678-83
 
22) Wattel E et al : Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein : results of a randomized study. Br J Haematol 1998 ; 102 : 1015-24
 
23) Beran M et al : Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999 ; 17 : 2819-30
 
24) Fenaux P et al : Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol 2009 ; 10 : 223-32
 
25) Itzykson R et al : Long-term outcome of higher-risk MDS patients treated with azacitidine : an update of the GFM compassionate program cohort. Blood 2012 ; 119 : 6172-3
 
26) 日本造血細胞移植学会データセンター : 日本造血細胞移植学会平成24年度全国調査報告書, 2013, p167-81
 
P.469 掲載の参考文献
1) Dan K et al : A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Int J Hematol 1992 ; 55 : 287-92
 
2) Fujimura K et al : Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenia purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005 ; 81 : 162-8
 
3) Mazzucconi MG et al : Treatment of idiopathic thrombocytopenic purpura (ITP) : results of a multicentric protocol. Hematologica 1985 ; 70 : 329-36
 
4) Bellucci S et al : Low doses v conventional doses of corticosteroids in immune thrombocytopenic purpura (ITP) : Results of randomized clinical trials in 160 children, 223 adults. Blood 1988 ; 71 : 1165-9
 
5) 藤村欣吾 : 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 2012 ; 53 : 433-42
 
6) Neunert C et al : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011 ; 117 : 4190-207
 
7) 蔵本淳 : 多施設共同研究による摘脾療法の遠隔成績. 厚生省特定疾患「特発性造血障害」調査研究班平成4年度研究業績報告書, 1993, p130-3
 
8) Stasi R et al : Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995 ; 98 : 436-42
 
9) Shirasugi Y et al : Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients : a double-blind, randomized Phase III clinical trial. Int J Hematol 2011 ; 94 : 71-80
 
10) Tomiyama Y et al : A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012 ; 10 : 799-806
 
11) Shirasugi Y et al : An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol 2012 ; 95 : 652-9
PubMed
12) Gernsheimer TB et al : Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010 ; 8 : 1372-82
 
13) Patel VL et al : Outcome 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012 ; 119 : 5989-95
PubMed
14) Cortelazzo S et al : High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991 ; 77 : 31-3
 
15) Portielje JEA et al : Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001 ; 97 : 2549-54
 

VIII. 巻末付録

P.477 掲載の参考文献
1) Seyffart G : Drug dosage in renal insufficiency, Kluwer academic publishers, 1991
 
2) Olyaei AJ et al : Prescribing drugs in renal disease, Brenner & Rector's The Kidney, 6th ed, 2000 ; p2606-53
 
3) Nolde-Hurlbert B : Drug removal during dialysis. Dial Transpl 1993 ; 22 : 316-22
 
4) Fuger K et al : Dialyzability of cytotoxic drugs. Experimental studies in vitro. Oncology 1990 ; 13 : 289-94
 
5) Micromedex, vol 108, Thomson Healthcare, 2001
 
6) Niscola P et al : Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther 2011 ; 11 : 415-32
 
P.483 掲載の参考文献
1) Von Hoff DD et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979 ; 91 : 710-7
 
2) Dukart G : Cardiac events in patients receiving mitoxantrone. Comprehensive Guide to the Therapeutic Use of Novantrone, Pharma Libri, 1984, p65-74
 
3) Anderlini P et al : Idarubicin cardiotoxicity : a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995 ; 13 : 2827-34
 
4) Herait P et al : Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 1992 ; 28A : 1670-6
 
5) Von Hoff DD et al : Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977 ; 62 : 200-8
 
6) Singal PK et al : Doxorubicin-induced cardiomyopathy. N Engl J Med 1998 ; 339 : 900-5
 
7) Siveski N et al : Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995 ; 91 : 10-5
 
8) Hori S et al : Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gann 1977 ; 68 : 685-90
 
P.496 掲載の参考文献
1) 阿部達生 (編著) : 造血器腫瘍アトラス 第3版, 日本医事新報社, 2000
 
2) 佐藤裕子 : 染色体異常. 新しい診断と治療のABC (36) 急性白血病, 大野竜三 (編), 最新医学社, 2006
 
3) 朝長万左男 (編著) : 染色体異常の基礎と臨床, 医薬ジャーナル社, 2006
 
4) Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2015), Mitelman F et al eds (http://cgap.nci.nih.gov/Chromosomes/Mitelman)
 
5) Melo JV : BCR/ABL gene variants. Baillieres Clin Haematol 1997 ; 10 : 203-22
PubMed
6) Bloomfield CD et al : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998 ; 58 : 4173-9
 
7) Sainty D et al : A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000 ; 96 : 1287-96
PubMed
8) Schlenk RF et al : Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 ; 358 : 1909-18
PubMed
9) Swerdlow SH et al eds : WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, IARC Press, 2008
 
10) Aukema ST et al : Double-hit B-cell lymphomas. Blood 2011 ; 117 : 2319-31
 
P.497 掲載の参考文献
1) Swerdlow SH et al eds : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, 2008
 
P.507 掲載の参考文献
1) 日本医薬品集フォーラム (監) : 日本医薬品集 医療薬 2015 年版, じほう, 2014
 
P.508 掲載の参考文献
1) 厚生労働省HP (http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000084783.html)
 
2) 難病情報センターHP (http://www.nanbyou.or.jp/)
 
3) 東京都福祉保健局HP (http://www.fukushihoken.metro.tokyo.jp/iryo/)
 
P.511 掲載の参考文献
1) 日本医薬品集フォーラム (監) : 日本医薬品集 医療薬 2015年版, じほう, 2014
 

書評

最近チェックした商品履歴

Loading...